Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells

被引:54
作者
Hasan, M. K. [1 ]
Yu, J. [1 ]
Chen, L. [1 ]
Cui, Bing [1 ]
Widhopf, G. F., II [1 ]
Rassenti, L. [1 ]
Shen, Z. [2 ]
Briggs, S. P. [2 ]
Kipps, T. J. [1 ]
机构
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA
关键词
RECEPTOR TYROSINE KINASE; B-CELLS; HEMATOPOIETIC LINEAGE; ACTIN POLYMERIZATION; CRD DOMAIN; PROTEIN; CHEMOTAXIS; FAMILY; SPECIFICITY; EXPRESSION;
D O I
10.1038/leu.2017.133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL). We found that ROR1 associates with hematopoietic-lineage-cell-specific protein 1 (HS1) in freshly isolated CLL cells or in CLL cells cultured with exogenous Wnt5a. Wnt5a also induced HS1 tyrosine phosphorylation, recruitment of ARHGEF1, activation of RhoA and enhanced chemokine-directed migration; such effects could be inhibited by cirmtuzumab, a humanized anti-ROR1 mAb. We generated truncated forms of ROR1 and found its extracellular cysteine-rich domain or kringle domain was necessary for Wnt5a-induced HS1 phosphorylation. Moreover, the cytoplamic, and more specifically the proline-rich domain (PRD), of ROR1 was required for it to associate with HS1 and allow for F-actin polymerization in response to Wnt5a. Accordingly, we introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1 PRD at positions 784, 808, 826, 841 or 850 in potential SH3-binding motifs. In contrast to wild-type ROR1, or other ROR1(P -> A) mutants, ROR1(P(841)) A had impaired capacity to recruit HS1 and ARHGEF1 to ROR1 in response to Wnt5a. Moreover, Wnt5a could not induce cells expressing ROR1P(841) A to phosphorylate HS1 or activate ARHGEF1, and was unable to enhance CLL-cell motility. Collectively, these studies indicate HS1 plays an important role in ROR1-dependent Wnt5a-enhanced chemokine-directed leukemia-cell migration.
引用
收藏
页码:2615 / 2622
页数:8
相关论文
共 46 条
[1]   PROLINE-RICH SEQUENCES THAT BIND TO SRC HOMOLOGY-3 DOMAINS WITH INDIVIDUAL SPECIFICITIES [J].
ALEXANDROPOULOS, K ;
CHENG, GH ;
BALTIMORE, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3110-3114
[2]   Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia [J].
Baskar, Sivasubramanian ;
Kwong, Kayin ;
Hofer, Thomas ;
Levy, Jessica M. ;
Kennedy, Michael G. ;
Lee, Elinor ;
Staudt, Louis M. ;
Wilson, Wyndham H. ;
Wiestner, Adrian ;
Rader, Christoph .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :396-404
[3]   ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia [J].
Broome, H. Elizabeth ;
Rassenti, Laura Z. ;
Wang, Huan-You ;
Meyer, Lilly M. ;
Kipps, Thomas J. .
LEUKEMIA RESEARCH, 2011, 35 (10) :1390-1394
[4]   Molecular features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr protein-tyrosine kinase [J].
Brunati, AM ;
Donella-Deana, A ;
James, P ;
Quadroni, M ;
Contri, A ;
Marin, O ;
Pinna, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (11) :7557-7564
[5]   Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells [J].
Burger, JA ;
Burger, M ;
Kipps, TJ .
BLOOD, 1999, 94 (11) :3658-3667
[6]   High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients [J].
Butrym, Aleksandra ;
Majewski, Miroslaw ;
Dzietczenia, Justyna ;
Kuliczkowski, Kazimierz ;
Mazur, Grzegorz .
LEUKEMIA RESEARCH, 2012, 36 (07) :876-880
[7]   The Actin Regulatory Protein HS1 Interacts with Arp2/3 and Mediates Efficient Neutrophil Chemotaxis [J].
Cavnar, Peter J. ;
Mogen, Kevin ;
Berthier, Erwin ;
Beebe, David J. ;
Huttenlocher, Anna .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (30) :25466-25477
[8]   Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1 [J].
Choi, Michael Y. ;
Widhof, George F., II ;
Wu, Christina C. N. ;
Cui, Bing ;
Lao, Fitzgerald ;
Sadarangani, Anil ;
Cavagnaro, Joy ;
Prussak, Charles ;
Carson, Dennis A. ;
Jamieson, Catriona ;
Kipps, Thomas J. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 :S167-S169
[9]   High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia [J].
Cui, Bing ;
Ghia, Emanuela M. ;
Chen, Liguang ;
Rassenti, Laura Z. ;
DeBoever, Christopher ;
Widhopf, George F., II ;
Yu, Jian ;
Neuberg, Donna S. ;
Wierda, William G. ;
Rai, Kanti R. ;
Kay, Neil E. ;
Brown, Jennifer R. ;
Jones, Jeffrey A. ;
Gribben, John G. ;
Frazer, Kelly A. ;
Kipps, Thomas J. .
BLOOD, 2016, 128 (25) :2931-2940
[10]   Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy [J].
DaneshManesh, Amir H. ;
Mikaelsson, Eva ;
Jeddi-Tehrani, Mahmood ;
Bayat, Ali Ahmad ;
Ghods, Roya ;
Ostadkarampour, Mahyar ;
Akhondi, Mehdi ;
Lagercrantz, Svetlana ;
Larsson, Catharina ;
Osterborg, Anders ;
Shokri, Fazel ;
Mellstedt, Hakan ;
Rabbani, Hodjattallah .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) :1190-1195